An observational study in Pulmonary Arterial Hypertension, sponsored by Prisma Health-Upstate. Completed at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-04-13.
Sponsored by Prisma Health-Upstate · Observational
Explore the impact of drug candidate CS1 on pathological vascular remodeling of small pulmonary arteries in the disease pulmonary arterial hypertension (PAH). This sub-study for CS1-004 aims to utilize FRI, an innovative, non-invasive imaging technology to visualize how long-term use of CS1 influences structural changes in pulmonary arteries. This sub-study seeks to provide valuable insights into the potential of CS1 to transform PAH treatment in some patients enrolled in the Expanded Access Program (CS1-004).
761 studies on the registry are indexed under Pulmonary Arterial Hypertension; 142 are open to participants now.
This study's enrollment of 7 is below the median of 100 across 197 observational studies indexed under Pulmonary Arterial Hypertension.
Browse Pulmonary Arterial Hypertension studies →Prisma Health-Upstate is the lead sponsor of 74 studies on the registry; 7 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 10 (83%) have results posted.
Counted across the registry records on this site, refreshed daily.
Participation in the CS1-004 clinical trial at Prisma Health-Upstate
Exclusion Criteria:
All subjects in this study will undergo CT pulmonary angiography scans at baseline (+/- 2 months from start of drug therapy), 4 months and 12 months.
Diagnostic Test: CT Pulmonary Angiography Scan
Computed tomography (CT) pulmonary angiography scan of the chest with IV contrast
Ratio of BV5A to BV10A
Change from baseline to month 12 in the ratio BV5A/BV10A
Time frame: From baseline CT scan to 12 month CT scan
Ratio of BV5A to BV5APR
Change from baseline CT scan to 12 month CT scan regarding the ratio of the BV5A to BV5APR variable.
Time frame: From baseline CT scan to 12 month CT scan
Ratio of BV5A to BV5APRA
Change from baseline CT scan to 12 month CT scan regarding the ratio of the BV5A to BV5APRA variable.
Time frame: From baseline CT scan to 12 month CT scan
Plan to share: No
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Arterial Hypertension→
Prisma Health-Upstate